A Study of Brain Aging in Vietnam War Veterans
DOD-ADNI
Effects of Traumatic Brain Injury and Post Traumatic Stress Disorder on Alzheimer's Disease (AD) in Veterans Using Alzheimer's Disease Neuroimaging Initiative (ADNI)
4 other identifiers
observational
289
1 country
19
Brief Summary
Traumatic brain injury (TBI) and post traumatic stress disorder (PTSD) are common combat related problems and may be associated with a greater risk of Alzheimer's disease (AD). The purpose of this study is to examine the possible connections between TBI and PTSD, and the signs and symptoms of AD on Veterans as they age. The information collected will help to learn more about how these injuries may affect Veterans of the Vietnam War as they grow older, as well as Veterans of the current wars in Iraq and Afghanistan, who also have these types of combat related injuries.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2012
Longer than P75 for all trials
19 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 31, 2012
CompletedFirst Posted
Study publicly available on registry
September 18, 2012
CompletedStudy Start
First participant enrolled
October 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 21, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 21, 2021
CompletedNovember 29, 2021
November 1, 2021
9 years
August 31, 2012
November 24, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Rates of change in brain regions based on neuroimaging
Rates of change in brain regions based on neuroimaging (magnetic resonance imaging \[MRI\] and amyloid positron-emission tomography \[PET\]) to show that those with TBI and/or PTSD have increased evidence for AD compared to Veteran controls
1 year
Rates of change in CSF amyloid beta and CSF tau/P tau levels based on biomarkers
Rates of change in CSF amyloid beta and CSF tau/P tau levels based on biomarkers such as cerebrospinal fluid (CSF) to show that those with TBI and/or PTSD have increased evidence for AD compared to Veteran controls
1 year
Rates of change in neuropsychological measures of memory and general cognitive performance
Rates of change in neuropsychological measures of memory and general cognitive performance based on cognitive measures to show that those with TBI and/or PTSD have increased evidence for AD compared to Veteran controls
1 Year
Secondary Outcomes (4)
Correlations within each group (TBI and PTSD) to assess whether baseline levels or rates of atrophy or cognitive decline are associated with severity of TBI or PTSD
1 year
Group differences in the patterns of amyloid deposition (from Florbetapir F 18) and brain atrophy
1 year
Group differences in white matter integrity as assessed with Diffusion Tension Imaging (DTI)
1 year
Rate of change of tau deposition as measured by 18F-AV-1451
1 year
Study Arms (6)
Traumatic Brain Injury (TBI)
65-100 Vietnam Veterans with Traumatic Brain Injury (TBI), but without PTSD, mild cognitive impairment (MCI)/dementia
Post Traumatic Stress Disorder (PTSD)
65-100 Vietnam Veterans with PTSD, but without TBI, MCI/dementia
Controls
65-100 Vietnam Veteran Controls without TBI or PTSD and comparable in age, gender, and education to the other cohorts
TBI w/ MCI
65-100 Vietnam Veterans with TBI but without PTSD who meet the criteria for MCI but not dementia
PTSD w/ MCI
65-100 Vietnam Veterans with PTSD but without TBI who meet the criteria for MCI but not dementia
Controls w/ MCI
65-100 Vietnam Veteran Controls without TBI or PTSD who meet the criteria for MCI but not dementia, and are comparable in age, gender, and education to the other cohorts
Eligibility Criteria
Vietnam Veterans
You may not qualify if:
- General (applies to each cohort):
- Subjects must be Veterans of the Vietnam War, 50-90 years of age. (Subjects 60-80 years of age will be selected first, while subjects \<60 or \>80 years of age will be added if recruitment numbers are too low in the 60-80 age range);
- Must live within 150 miles of the closest ADNI clinic in subject's area.
- Comparable in age, gender, and education with TBI and PTSD groups;
- May be receiving Veterans Affairs (VA) disability payments for something other than TBI or PTSD - or no disability at all.
- Subjects must have a documented history of moderate-severe non-penetrating TBI, which occurred during military service in Vietnam (identified from the Department of Defense or VA records);
- TBI will be defined as:
- Loss of consciousness,
- Post-traumatic amnesia \>24 hours, OR
- Alteration of consciousness or mental state \>24 hours
- Subjects who meet the Structured Clinical Interview 1 of the Diagnositic and Statistical Manual of Mental Disorders, Version IV, (Axis 1) - Text Revision \[SCID-I of the DSM-IV-TR\] criteria for current/chronic PTSD (identified by records, and verified by our telephone assessments);
- In addition to meeting DSM-IV-TR criteria for current/chronic PTSD, subjects must have a minimum current Clinician Administered PTSD Scale (CAPS) score of 50 as determined by telephone assessment;
- The PTSD symptoms contributing to the PTSD Diagnosis and Current CAPS score must be related to a Vietnam War related trauma.
- General (applies to each cohort):
- MCI/dementia;
- +16 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Southern Californialead
- United States Department of Defensecollaborator
- Telemedicine & Advanced Technology Research Centercollaborator
- Northern California Institute of Research and Educationcollaborator
- San Francisco Veterans Affairs Medical Centercollaborator
- Alzheimer's Therapeutic Research Institutecollaborator
Study Sites (19)
Banner Sun Health Research Institute
Sun City, Arizona, 85351, United States
University of California, Irvine
Irvine, California, 92697, United States
University of California, San Diego
La Jolla, California, 92093, United States
University of Southern California
Los Angeles, California, 90033, United States
VA Palo Alto HSC / Stanford School of Medicine
Palo Alto, California, 94304, United States
University of California, San Francisco
San Francisco, California, 94117, United States
Georgetown University
Washington D.C., District of Columbia, 20057, United States
Howard University
Washington D.C., District of Columbia, 20060, United States
Wien Center for Clinical Research
Miami Beach, Florida, 33140, United States
Premiere Research Institute
West Palm Beach, Florida, 33407, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Cornell Medical Center
New York, New York, 10021, United States
Columbia University
New York, New York, 10032, United States
University of Rochester Medical Center
Rochester, New York, 14620, United States
Duke University Medical Center
Durham, North Carolina, 27710, United States
Roper St Francis Healthcare
Charleston, South Carolina, 29401, United States
U of WA / VA Puget Sound Alzheimer's Disease Research Center
Seattle, Washington, 98108, United States
University of Wisconsin
Madison, Wisconsin, 53705, United States
Related Publications (4)
Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2005 Jul;1(1):55-66. doi: 10.1016/j.jalz.2005.06.003.
PMID: 17476317BACKGROUNDWeiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010 May;6(3):202-11.e7. doi: 10.1016/j.jalz.2010.03.007.
PMID: 20451868BACKGROUNDJack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6.
PMID: 20083042BACKGROUNDVemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009 Jul 28;73(4):294-301. doi: 10.1212/WNL.0b013e3181af79fb.
PMID: 19636049BACKGROUND
Related Links
Biospecimen
blood, urine, cerobrospinal fluid
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Michael W. Weiner, MD
University of California, San Francisco
- PRINCIPAL INVESTIGATOR
Paul Aisen, MD
USC Alzheimer's Therapeutic Research Institute (ATRI)
- PRINCIPAL INVESTIGATOR
Ronald Petersen, MD, PhD
Mayo Clinic
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 31, 2012
First Posted
September 18, 2012
Study Start
October 1, 2012
Primary Completion
September 21, 2021
Study Completion
September 21, 2021
Last Updated
November 29, 2021
Record last verified: 2021-11